Relationship between estrogen receptor and cisplatin resistance in human ovarian cancer SKOV3 cells
10.13699/j.cnki.1001-6821.2017.04.016
- VernacularTitle:雌激素受体与卵巢癌SKOV3细胞顺铂耐药的相关性研究
- Author:
Jun LI
1
;
En-Ling LIU
;
Li YANG
Author Information
1. 唐山市工人医院产科
- Keywords:
ovarian cancer;
estrogen receptor;
cisplatin;
drug resistance;
apoptosis
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(4):347-350
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between estrogen receptor and cisplatin resistance in ovarian cancer SKOV3 cells.Methods A total of 30 mice were inoculated 4 × 106 ovarian cancer SKOV3 cells to establish the xenograft tumor model with human ovarian cancer SKOV3 cells.And they were randomly divided to control group and test group with 15 cases per group.Control group was given 0.9％ NaC1,intraperitoneal injection,once a week,a total of 5 times.Test group was given cisplatin 20 mg · kg-1,intraperitoneal injection,once a week,a total of 5 times.Then the ovarian cancer SKOV3 cells were collected from two groups.The expression of estrogen receptor in ovarian cancer SKOV3 cells was detected by immunocytochemistry and flow cytometry.MTT assay and flow cytometry were used to detect the effect of proliferation and apoptosis in ovarian cancer SKOV3 cells with different concentrations of cisplatin (0,1,5,10,15,20 μg · mL-1) combined with ICI182 (0,1,5,10,20 μmol · L-1) or alone.Results In control and test groups,the immune cell chemistry score (HIS score) were (10.04 ± 2.93),(6.73 ±2.37)points;the expression of estrogen receptor were 231.39 ± 15.33,205.81 ± 12.50 with significant difference(P ＞ 0.05).ICI182 had anti-proliferative effect on the control and test groups with dose-dependent and time-dependent manners.The inhibition rate of proliferation significantly increased by ICI182 combined with cisplatin (P ＜0.01).After treated with 10 μmol · L-1 ICI182 + 10 μg · mL-1 cisplatin in the test group and control group,the inhibition rates were (70.07-± 0.64) ％ and (82.13 ± 0.87) ％ with significant difference (P ＜ 0.01).Conclusion Estrogen receptor is involved in the process of drug resistance,and it is possible to reverse the cisplatin resistance of ovarian cancer cells by inhibiting estrogen receptor protein by ICI182.
